Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Wire Syria.
Press releases published on September 16, 2025
Italfarmaco Announces Exclusive Distribution Agreement with Multicare Pharma for DMD Treatment Givinostat in Brazil
Italfarmaco has entered into an agreement with Multicare for the regulatory approval and distribution of givinostat as a treatment for Duchenne muscular dystrophy in Brazil. MILAN, Italy, and SÃO PAULO, Brazil, September 16, 2025 – Italfarmaco S.p.A. today …
Osivax Announces First Participant Vaccinated in Phase 2b Trial Evaluating Broad-Spectrum Influenza A Vaccine Candidate, OVX836
Phase 2b to assess efficacy, safety, and immunogenicity 2,850 participants to be enrolled across European countries Lyon, France and Liège, Belgium – September 16, 2025 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum …
Aicuris Announces Upcoming Oral and Poster Presentations at ID Week 2025
Company will provide an overview of the pritelivir clinical development program in two oral presentations including a comprehensive Phase 2 data overview Updated safety and pharmacokinetic results of the Phase 1 trial with the antiviral therapy AIC468 …
Manchester charity recognises UK hero volunteers
MANCHESTER, United Kingdom, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Manchester-based humanitarian charity, Human Appeal, announced its second awards ceremony, Purple Legacy Awards 2025, that recently took place. The first was organised in 2024 to celebrate the …
Cumulus Oncology Strengthens Board of Directors & Scientific Advisory Team
EDINBURGH, Scotland, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Cumulus Oncology, an oncology and inflammation focused biotech, announces the expansion of its Board of Directors (BoD) and scientific advisory team with the appointment of Dr Manuel Aivado to the BoD …
New Imprivata Report Finds that UK Hospitals Save More Than £522K Annually with Shared-Use Mobile Devices, but Gaps in Strategy Pose Risks
LONDON, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Imprivata, a leading provider of access management solutions for healthcare and other mission-critical industries, today released new research which finds that each UK healthcare facility saves an average of £522, …
ANEUVO präsentiert ExaStim® Therapie auf der RehaCare 2025 und ISCoS 2025
LOS ANGELES, Sept. 16, 2025 (GLOBE NEWSWIRE) -- ANEUVO kündigte heute seine Teilnahme an zwei der weltweit einflussreichsten internationalen Veranstaltungen für die Rehabilitation und Versorgung von Querschnittlähmung (QSL) an: der RehaCare 2025 in …
Cantoni Therapeutics secures financing to advance novel non-incretin obesity drug into IND enabling phase
Brabant Development Agency (BOM) and angel investor join lead investor Libertatis Ergo Holding (LEH) in providing funding, with additional financial support from Brabant Startup Fund (BSF) Cantoni awarded validatioNN grant from Novo Nordisk to support …
Transforming Global Healthcare: Inteleos Debuts Sonography Certification at Eight New UAE Testing Centers
New Locations Unlock Regional Access to Certification, Expand Opportunity for Professionals to Obtain ISO-Certified Credentials Healthcare credentialing leader advances equity and excellence in diagnostic ultrasound for clinicians throughout the UAE …
Basilea erhält im Rahmen ihrer BARDA-Vereinbarung USD 25 Mio. für die weitere Entwicklung der neuen Antipilzmittel Fosmanogepix und BAL2062
Ad hoc-Mitteilung gemäss Art. 53 KR Allschwil, 16. September 2025 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN), ein biopharmazeutisches Unternehmen mit bereits vermarkteten Produkten und dem Ziel, Patientinnen und Patienten zu helfen, die an schweren …
Basilea receives USD 25 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 16, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal …